COPD stem cell therapy - SMSbiotech
Alternative Names: Lung therapy - SMSbiotechLatest Information Update: 26 Jul 2024
At a glance
- Originator SMSbiotech
- Class Stem cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Chronic obstructive pulmonary disease
Most Recent Events
- 17 May 2024 Phase-I clinical trials in Chronic obstructive pulmonary disease (Parenteral) before May 2024
- 17 May 2024 Preclinical trials in Chronic obstructive pulmonary disease in USA (Parenteral) before May 2024
- 17 May 2024 Pharmacodynamics data from a preclinical trial in Chronic obstructive pulmonary disease presented at the 120th International Conference of the American Thoracic Society (ATS-2024)